Edwin A. Basak
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: July 31, 2025
Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma.
Journal: Clinical pharmacology and therapeutics
Published: July 04, 2025
Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors.
Journal: Cancer treatment reviews
Published: October 04, 2023
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 30, 2022
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 06, 2022
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Journal: Journal for immunotherapy of cancer
Published: April 27, 2021
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
Journal: Journal for immunotherapy of cancer
Published: November 15, 2020
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: April 09, 2020
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Journal: Thyroid : official journal of the American Thyroid Association
Published: March 11, 2020
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.
Journal: Journal for immunotherapy of cancer
Published: May 27, 2019
Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 04, 2018
CD45RA+CCR7- CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab.
Journal: Journal for immunotherapy of cancer
Published: September 19, 2018
Last Updated: 09/26/2026